IT1255770B - Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi - Google Patents

Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi

Info

Publication number
IT1255770B
IT1255770B ITMI921235A ITMI921235A IT1255770B IT 1255770 B IT1255770 B IT 1255770B IT MI921235 A ITMI921235 A IT MI921235A IT MI921235 A ITMI921235 A IT MI921235A IT 1255770 B IT1255770 B IT 1255770B
Authority
IT
Italy
Prior art keywords
translocation
antisense oligonucleotides
chromosome
pharmaceutical compositions
relates
Prior art date
Application number
ITMI921235A
Other languages
English (en)
Inventor
Susanna Morelli
Angelo Nicolin
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Priority to ITMI921235A priority Critical patent/IT1255770B/it
Publication of ITMI921235A0 publication Critical patent/ITMI921235A0/it
Priority to PCT/EP1993/001287 priority patent/WO1993024653A1/en
Publication of ITMI921235A1 publication Critical patent/ITMI921235A1/it
Application granted granted Critical
Publication of IT1255770B publication Critical patent/IT1255770B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invenzione riguarda oligonucleotidi antisenso (aODN) che comprendono sequenze di nucleotidi caratterizzati dalla possibilità di ibridizzare, anche all'interno delle cellule umane, con regioni delle molecole del codice genetico originate dalla traslocazione di un tratto di cromosoma 18 su altri cromosomi, in particolare il cromosoma 14. La traslocazione cromosomica è la causa di numerose forme patologiche, in particolare tumori. L'inibizione degli effetti biologici della traslocazione da parte di oligonucleotidi antisenso ha significato conoscitivo, diagnostico e terapeutico.L'invenzione riguarda l'uso di tali antisenso per lo studio la diagnosi e la terapia dei tumori originati dalla traslocazione cromosomica t (14;18) e le modificazioni chimiche e farmaceutiche atte a renderle idonee per la somministrazione in campo umano.
ITMI921235A 1992-05-22 1992-05-22 Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi IT1255770B (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITMI921235A IT1255770B (it) 1992-05-22 1992-05-22 Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
PCT/EP1993/001287 WO1993024653A1 (en) 1992-05-22 1993-05-21 Antisense oligonucleotides with antitumoral activity, pharmaceutical compositions which comprise them, and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI921235A IT1255770B (it) 1992-05-22 1992-05-22 Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi

Publications (3)

Publication Number Publication Date
ITMI921235A0 ITMI921235A0 (it) 1992-05-22
ITMI921235A1 ITMI921235A1 (it) 1993-11-22
IT1255770B true IT1255770B (it) 1995-11-15

Family

ID=11363352

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI921235A IT1255770B (it) 1992-05-22 1992-05-22 Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi

Country Status (2)

Country Link
IT (1) IT1255770B (it)
WO (1) WO1993024653A1 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1189573A (ja) * 1994-10-14 1999-04-06 Yutaka Shindo アポトーシス関与遺伝子
IT1275862B1 (it) * 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
IT1276642B1 (it) * 1995-03-03 1997-11-03 Consiglio Nazionale Ricerche Trascritto antisenso presente in linfociti b ed oligodeossinucleotidi sintetici utili per inibirne l'azione
DE19610255B4 (de) * 1996-03-15 2004-11-04 Universität Heidelberg Verfahren zur Herstellung von Nukleinsäuresequenzen und Verfahren zum Nachweis von Translokationen zwischen Chromosomen
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0878552A1 (en) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
JP2002513587A (ja) 1998-05-04 2002-05-14 ダコ エー エス 染色体異常を検出するための方法およびプローブ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
CA2091759A1 (en) * 1990-09-17 1992-03-18 Dale E. Bredesen Method and composition for controlling proliferation of cells
EP0590090A4 (en) * 1991-06-18 1995-04-12 Univ Temple SELECTIVE INHIBITATION OF LEUKEMIC CELL PROLIFERATION BY -I (BCR-ABL) ANTISENS OLIGONUCLEOTIDES.

Also Published As

Publication number Publication date
ITMI921235A1 (it) 1993-11-22
ITMI921235A0 (it) 1992-05-22
WO1993024653A1 (en) 1993-12-09

Similar Documents

Publication Publication Date Title
Young et al. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals
TWI272273B (en) Platinum compounds
Weiss et al. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation.
Dietrich et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo
Cholody et al. Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumors
Takusagawa et al. The structure of a pseudo intercalated complex between actinomycin and the DNA binding sequence d (GpC)
IT1255770B (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR0017048A (pt) Pró-drogas de bisamidato fosfonato
HUP0100786A2 (hu) Helyettesített 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanonok, felhasználásuk egyes központi és perifériás idegrendszeri betegségek kezelésére és e vegyületeket tartalmazó gyógyszerkészítmények
ATE475716T1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
MXPA05012645A (es) Piridopirazinas novedosas y su uso como moduladores de cinasa.
TNSN99177A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
Eisen et al. Peripheral nerve function in long‐term therapy with diphenylhydantoin: A clinical and electrophysiologic correlation
Johnson et al. Comparison of delta opiate receptor agonist induced reward and motor effects between the ventral pallidum and dorsal striatum
ATE215099T1 (de) Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie
CA2276306A1 (en) Loss of imprinting-based in vitro diagnostic method to determine the propensity to develop cancer
Liu et al. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells
DE602004027255D1 (de) Peptidische Verbindungen und deren Ableitungen für die Behandllung von menschlichen Krankheiten durch Hemmung der Signalübertragung über Wachstumfaktoren
Kolarić et al. Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors
Double et al. Chemotherapy of transplantable adenocarcinomas of the colon in mice. II. Development and characterization of an ascitic line
Lea et al. Action of Miracil D and related compounds on DNA and RNA synthesis in regenerating liver and hepatomas
Lee et al. Deferoxamine-induced cytotoxicity in human neuronal cell lines: protection by free radical scavengers
Köpf-Maier et al. Tumor inhibition by ferricenium complexes. Activity against some solid experimental tumors
Peter et al. Oxidative phosphorylation and calcium transport by sarcotubular vesicles in myotonic dystrophy

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970522